文献速递乳腺癌放疗

新辅助化疗后病理缓解预测三阴性乳腺癌局部区域控制

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.
PubMed 文献 · Adv Radiat Oncol · 2017-02-07

中位随访32.5个月,乳腺或淋巴结残留病变者30个月局部区域复发(LRR)显著高于pCR者,无病生存(DFS)也更差。

要点

  • 尽管使用辅助放疗,残留病变者局部失败率仍显著更高。

核心结论

  • 接受新辅助化疗的三阴性乳腺癌患者,手术时乳腺或淋巴结有残留病变者,尽管接受辅助放疗,局部区域失败率仍显著高于pCR者,DFS也更差。

主要发现

  • 72例接受放疗的三阴性乳腺癌患者中位随访32.5个月,pCR率为36%。

关键数值与推荐

  • ypT0定义为乳腺无残留浸润性疾病,ypN0定义为淋巴结无残留浸润性疾病。
  • LRR定义为乳腺、胸壁或区域淋巴结的任何失败。
  • 保乳与全乳切除的LRR差异未达显著性(8% vs 17%)。
  • DFS差异与手术类型无显著关联。

临床怎么用

  • 对于新辅助化疗后乳腺或淋巴结有残留病变的三阴性乳腺癌患者,即使接受辅助放疗,仍应关注较高的局部区域失败和DFS事件风险。
  • 对残留病变患者强化治疗的策略值得进一步研究。

局限性

  • 中位随访32.5个月,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to determine the impact of pathologic response after neoadjuvant chemotherapy in triple negative breast cancer (TNBC) on the subsequent risk of locoregional recurrence (LRR) and disease-free survival (DFS) in the setting of adjuvant radiation therapy. METHODS AND MATERIALS: This was an institutional review board-approved retrospective chart review of patients with clinical stage I-III breast cancer treated with neoadjuvant chemotherapy, local surgery (breast conservation or mastectomy), and adjuvant radiation therapy between 1997 and 2015. Medical records were reviewed for clinical stage, tumor grade and subtype, neoadjuvant chemotherapy regimen, type of surgery, pathologic stage, use of radiation therapy, date and location of recurrence, and date of death. Molecular subtypes were defined using immunohistochemistry and histologic grade. ypT0 and ypN0 were defined as no residual invasive disease in breast or nodes, respectively. LRR was defined as any failure within the breast, chest wall, or regional lymph nodes. Statistical analysis was performed; LRR and DFS rates over 30 months were determined from Kaplan-Meier plots. RESULTS: Ninety-four patients with TNBC were analyzed, of whom 72 received radiation therapy. This subgroup was isolated for further investigation. Median follow-up was 32.5 months in this group. The pathologic complete response (pCR) rate was 36%, and presence or absence of disease in breast and/or nodes was significantly predictive of LRR. In TNBC patients who received radiation therapy, 30-month LRR was 22% in 41 patients with ypT+ versus 0% in 31 patients with ypT0 (P = .003), 23% in 31 patients with ypN+ versus 5% in 41 patients with ypN0 (P = .016), and 20% in 46 patients with residual disease in breast or nodes versus 0% in 26 patients with pCR (P = .015). The difference in the rate of LRR between those who underwent lumpectomy versus mastectomy did not reach significance (8% vs 17%, respectively). Furthermore, patients with residual disease had a higher rate of DFS events (hazard ratio, 3.58; 95% confidence interval, 1.37-9.41; P = .006). The difference in DFS was not significantly associated with the type of surgery received. CONCLUSIONS: Patients with TNBC treated with neoadjuvant chemotherapy who have residual disease in the breast or lymph nodes at the time of surgery have significantly higher rates of locoregional failure and lower DFS compared with those with a pCR despite the use of adjuvant radiation therapy. Strategies to intensify therapy for patients with residual disease warrant further investigation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen VE, Gillespie EF, Zakeri K, et al. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. Adv Radiat Oncol. 2017. PMID: 28740920. doi:10.1016/j.adro.2017.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。